Why did Green Cross change strategy over its hemophilia treatment?
Green Cross changed its target of business to the Chinese market, as suspending the U.S. clinical trial of the hemophilia treatment ‘Greengene F,’ which has been conducted since 2012.
The company was known to judge being stubborn on expansion into the U.S. market is not reasonable since the clin...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
